Testing Name
CLOSEDIPO Date: 29 Nov - 3 Dec 2024
Listing Date: 6 Dec 2024
Price Range
Rs.420 to Rs.441
Issue Size
846 Cr
Min Investment
₹14,700
Lot Size
35 Shares
Schedule of Testing Name
Issue open date
29 Nov 2024
Issue close date
3 Dec 2024
UPI mandate deadline
3 Dec 2024 (5 PM)
Allotment finalization
4 Dec 2024
Share credit
5 Dec 2024
Listing date
6 Dec 2024
Mandate end date
17 Dec 2024
Issue size
| Funds Raised in the IPO | Amount |
|---|---|
| Overall | 846 Cr |
| Fresh Issue | 0 Cr |
| Offer for Sale | 0 Cr |
Allotment DetailsNew
| Allotment Timeline | Details |
|---|---|
| Allotment Date | 4 Dec 2024 |
| Allotment Link | {Link} |
Grey Market PremiumNew
Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.
| Date | Ipo Price | GMP | Estimated Listing Price |
|---|---|---|---|
| 12 Dec 2024 | ₹441 | ₹419 | ₹860 (95%) |
| 11 Dec 2024 | ₹441 | ₹221 | ₹662 (50%) |
| 10 Dec 2024 | ₹441 | ₹397 | ₹838 (90%) |
Performance Testing Name
| Issue Price | Listing Gain | Current Market Price | P/L |
|---|---|---|---|
| Rs.420 to Rs.441 | ₹ 428 (-5%) | ₹ 500 | 13.38% |
About Testing Name
Suraksha Diagnostic Limited, incorporated in 2005, operates as an integrated diagnostic service provider in East India, covering pathology, radiology, and medical consultation. With central reference and satellite labs, along with diagnostic centres, the company provides accessible diagnostic services, accredited by the College of American Pathologists and NABL, across regions including West Bengal, Bihar, Assam, and Meghalaya.
| Founded in | 2005 |
| Managing director | Dr. Somnath Chatterjee and Ms. Ritu Mittal |
| Parent organization | Suraksha Diagnostic Ltd |
Financial Overview
Strengths
- Leading presence in eastern India’s diagnostic market with growth potential in a fragmented industry
- Provides comprehensive diagnostics including pathology radiology and consultations.
- Equipped with advanced clinical infrastructure and skilled personnel for reliable services.
- Recognized brand with a focus on quality supporting individual consumer business.
Risks
- The company’s business relies heavily on West Bengal and any loss of business in this region may negatively impact overall performance.
- Keeping up with new tests and technology is essential; falling behind could weaken the company’s competitive edge.
- The company depends on third-party vendors for testing equipment and supply disruptions could affect operations.
- Franchisees run many collection centres and failing to meet the required standards could impact quality and reputation.
- The diagnostics industry is highly competitive which could lead to price cuts that affect profits.
- The company has significant debt and financial agreements that may reduce flexibility and affect financial health.
Subscription Figures
| Category | Subscription (No. of times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 2 |
| Non-Institutional Investors (NIIs) | 3 |
| Retail Individual Investors (RIIs) | N/A |
| Employee | N/A |
| Total | 10 |